David Juurlink | |
---|---|
Born | 1968 (age 55–56) New Glasgow, Nova Scotia, Canada |
Nationality | Canadian |
Alma mater | Dalhousie University[1] |
Occupation | Physician |
David Juurlink (/ˈjʊərlɪŋk/ YURE-link;[2] born New Glasgow, Nova Scotia) is a Canadian pharmacologist and internist. He is head of the Clinical Pharmacology and Toxicology division at Sunnybrook Health Sciences Centre in Toronto, Ontario, as well as a medical toxicologist at the Ontario Poison Centre and a scientist at the Institute for Clinical Evaluative Sciences. He is known for researching adverse effects caused by drug interactions, with some of this research funded by a New Investigator Award from the Canadian Institutes for Health Research.[3] He has been very critical of his fellow physicians' regular prescribing of dangerous opioids like Tramadol[4] and fentanyl.[5][6] In June 2017, he published a letter analyzing citations to "Addiction Rare in Patients Treated with Narcotics", a 1980 letter in The New England Journal of Medicine that has often been cited to claim that opioids like OxyContin are rarely addictive.[7]